Modulation of α-synuclein aggregation by dopamine in the presence of MPTP and its metabolite
Related Experiment Video
Updated: Jun 3, 2026

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Prashant N Jethva1, Jay R Kardani, Ipsita Roy
1Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), SAS Nagar, Punjab, India.
Abstract:
The neurotransmitter dopamine has been shown to inhibit fibrillation of α-synuclein by promoting the formation of nonamyloidogenic oligomers. Fibrillation of α-synuclein is accelerated in the presence of pesticides and the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). The aim of this study was to determine whether dopamine continues to have an adverse effect on the fibrillation of α-synuclein in the presence of MPTP and its metabolite 1-methyl-4-phenylpyridinum ion (MPP(+) ). We also attempted to answer the ambiguous question of whether conversion of MPTP to MPP(+) is required for the fibrillation of α-synuclein. For this, α-synuclein was incubated in the presence of MPTP and MPP(+) along with dopamine. The fibrillation of α-synuclein was monitored by Thioflavin T fluorescence and immunoblotting. The morphology of the aggregates formed was observed using scanning electron microscopy. The concentrations of the neurotoxin and its metabolite were estimated by reverse phase HPLC. We found definitive evidence that the conversion of MPTP to MPP(+) is not required for aggregation of α-synuclein. MPP(+) was found to accelerate the rate of α-synuclein aggregation even in the absence of components of mitochondrial complex I. In contrast to the effect of dopamine on the aggregation of α-synuclein alone, in the presence of MPTP or MPP(+) , the aggregates formed are Thioflavin T-positive and amyloidogenic. Thus, the effect of dopamine on the nature of aggregates formed in case of α-synuclein alone and in the presence of MPTP/MPP(+) is different.
Insights
Dopamine normally prevents alpha-synuclein fibrillation. However, with neurotoxins like MPTP or MPP+, dopamine promotes amyloidogenic aggregates, indicating a different effect in neurodegenerative conditions.
Area of Science:
- Neuroscience
- Biochemistry
- Toxicology
Background:
- Alpha-synuclein (α-synuclein) fibrillation is a hallmark of neurodegenerative diseases like Parkinson's.
- Dopamine typically inhibits α-synuclein fibrillation by promoting non-amyloidogenic oligomers.
- Pesticides and neurotoxins, such as MPTP, can accelerate α-synuclein fibrillation.
Purpose of the Study:
- To investigate dopamine's effect on α-synuclein fibrillation in the presence of MPTP and its metabolite MPP+.
- To determine if MPTP conversion to MPP+ is necessary for accelerating α-synuclein fibrillation.
Main Methods:
- Incubation of α-synuclein with MPTP and/or MPP+ in the presence of dopamine.
- Monitoring α-synuclein fibrillation using Thioflavin T fluorescence and immunoblotting.
- Characterizing aggregate morphology via scanning electron microscopy and quantifying neurotoxin levels using HPLC.
Main Results:
- MPP+ accelerates α-synuclein aggregation independently of MPTP conversion and mitochondrial complex I.
- In the presence of MPTP or MPP+, dopamine promotes the formation of Thioflavin T-positive, amyloidogenic α-synuclein aggregates.
- Dopamine's effect on aggregate formation differs significantly when neurotoxins are present compared to α-synuclein alone.
Conclusions:
- MPTP conversion to MPP+ is not required for initiating α-synuclein aggregation.
- MPP+ directly promotes α-synuclein aggregation, even without mitochondrial dysfunction.
- Dopamine's role in modulating α-synuclein aggregation is context-dependent, promoting harmful amyloid formation in the presence of neurotoxins.
Related Concept Videos
Parkinson Disease ll: Pathophysiology
Drugs Affecting Neurotransmitter Synthesis
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Neural Regulation
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
